Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corporation reports developments tied to blood volume measurement technology, including commercialization of its FDA-cleared Blood Volume Analysis diagnostics and the BVA-100 Blood Volume Analyzer. Company news commonly covers clinical data, cardiology and critical-care use cases, new customer programs, conference presentations, and product updates for rapid, portable BVA systems.
Daxor also issues updates on financial results, shareholder communications, capital actions, and market expansion for its ezBVA Lab workflow and related diagnostic services. Its coverage centers on precision fluid management, heart failure, ICU care, and adoption of direct blood, plasma, and red-cell volume measurement in clinical settings.
Daxor (NASDAQ: DXR) announced it intends to change its primary reporting framework from the Investment Company Act to the Securities Exchange Act, reflecting its shift to an operating medical diagnostics business focused on Blood Volume Analysis (BVA). The company cited customer growth, revenue increases, and FDA clearance of its next-generation analyzer. Daxor expects to complete regulatory steps by the end of Q2, subject to required filings and approvals, and said Exchange Act reporting will provide standardized GAAP disclosures and improved investor comparability.
Daxor (NasdaqCM: DXR) entered a definitive agreement for a registered direct offering of 765,958 shares at $11.75 per share, expected to close on or about January 26, 2026. Gross proceeds are expected to be approximately $9 million before placement agent fees and offering expenses. The company intends to use net proceeds for general corporate purposes, including working capital. Lake Street Capital Markets is the exclusive placement agent. The related Form N-2 registration was declared effective on January 20, 2026. The offering will be made only by prospectus supplement and accompanying prospectus and will be filed with the SEC.
Daxor (Nasdaq: DXR) announced on November 25, 2025 that its Blood Volume Analysis (BVA) platform expanded into three new facilities, combining on-site analyzer deployments with its CLIA-certified ezBVA Lab Service for next-day results. New adoptions include an Upper Midwest integrated health system using ezBVA for high-volume cardiology and heart failure diagnostics, an Ohio academic medical center using ezBVA for outpatient advanced heart failure management, and a Southwest cardiology group practice that onboarded the new on-site BVA analyzer for immediate in-office assessments. Management said the dual on-site plus lab approach is driving accelerating market traction and anticipated continued sales momentum among clinicians focused on precision fluid management.
Daxor (Nasdaq: DXR) announced that President and CEO Michael Feldschuh will meet institutional investors at the Maxim Growth Summit on October 22–23, 2025 at the Hard Rock Hotel in New York City.
Mr. Feldschuh will be available for one-on-one investor meetings and will meet with senior Maxim analysts; participation in the summit is by invitation. Institutional investors seeking meetings are directed to contact Bret Shapiro, COO – Head of Capital Markets, COREIR, via phone (561)-479-8566 or email brets@coreir.com. For the full summit agenda visit www.maximgrp.com/2025-growth-summit.
Daxor (NASDAQ: DXR) will exhibit at the MedAxiom Cardiovascular Transforum Fall'25 at the JW Marriott Austin from October 16–18, 2025. The company plans to debut its next‑generation BVA diagnostic system and demonstrate how the technology addresses hospital readmissions and resource optimization for cardiovascular providers. CEO Michael Feldschuh said the launch is expected to accelerate sales momentum and support wider commercial adoption by connecting with cardiovascular innovators.
The appearance positions Daxor to showcase clinical and operational benefits to health systems and potential customers attending the conference in Austin, TX.
Daxor Corporation (Nasdaq: DXR) unveiled its newly FDA-cleared next-generation Blood Volume Analysis (BVA) analyzer at the Heart Failure Society of America (HFSA) Annual Scientific Meeting. The new system features enhanced ease of use, speed, and over 95% accuracy.
Three pivotal studies from leading institutions validated BVA technology's effectiveness: Banner University Medical Center reported zero unplanned hospital admissions for optimally managed patients, Wellstar Health System demonstrated improved LVAD outcomes with increased survival rates and reduced readmissions, and Geisinger Medical Center confirmed BVA's utility in diagnosing Cardiac Amyloidosis.
Daxor Corporation (Nasdaq: DXR), the leader in blood volume measurement technology, will showcase its newly FDA-cleared next-generation blood volume analyzer (BVA) at the Heart Failure Society of America Annual Scientific Meeting from September 26-29, 2025.
The new BVA system represents a significant technological advancement, being three times faster than the previous BVA-100™ model, requiring 50% less blood drawn from patients, and maintaining over 95% accuracy with a portable, battery-operated design. New clinical data validating BVA technology will be presented, including research from Wellstar Medical Group and Banner University Medical Center focusing on heart failure patient outcomes.
Daxor Corporation (Nasdaq: DXR) announced significant findings from a new pilot study published in the Journal of Critical Care, validating their Blood Volume Analysis (BVA) technology for COVID-19 and sepsis patients. The study revealed that 48% of COVID-19 patients were incorrectly assessed for fluid status by clinicians, highlighting the critical need for more accurate measurement tools.
The research demonstrated that sepsis patients showed higher albumin transudation rates compared to COVID-19 patients, indicating more severe blood vessel integrity breakdown. The study coincides with Daxor's recent FDA clearance in August 2025 for their new rapid BVA system, which is three times faster than their previous BVA-100™ analyzer while maintaining 95% accuracy.
Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. CEO and President Michael Feldschuh will deliver a presentation that will be available on-demand starting September 5, 2025, at 7:00 a.m. ET.
The conference will take place from September 8-10, 2025 at the Lotte New York Palace Hotel. Registered conference investors can schedule one-on-one meetings with Mr. Feldschuh and access the presentation through the conference registration portal.
Daxor Corporation (Nasdaq: DXR), the leader in blood volume measurement technology, released a mid-year shareholder update highlighting significant achievements in 2025. The company secured FDA clearance for its new rapid, lightweight Blood Volume Analysis System in August 2025, which is three times faster and more portable than its predecessor BVA-100.
Financial highlights include a 73% increase in unaudited revenues for H1 2025 compared to H1 2024, driven by diagnostic kit sales and military contracts. The company's net assets grew to $36.6 million, with NAV increasing to $7.15 per share, up $0.40 from June 2024.
Clinical validation strengthened with multiple studies, including research showing 2.61 times better survival in BVA-identified euvolemic heart failure patients. The company expanded market adoption with multiple new facility adoptions across the U.S. in 2025.